VHT vs. XPH: Cheaper and Broader Against Faster and Wilder
Two healthcare ETFs, two very different bets. Vanguard's VHT is cheaper, broader and pays more income; State Street's XPH has run harder and swung wider — including on Sept. 10.
Vanguard's broad healthcare ETF VHT charges lower fees and yields more than State Street's pharmaceuticals-focused XPH, which has posted stronger recent gains with higher volatility; VHT last closed at 311.27, down 0.65%, while XPH closed at 68.01, down 1.89%, on Sept. 10, 2026.
The choice between the two most-cited ways to own healthcare in an exchange-traded fund is not really a choice between two healthcare funds. It is a choice between owning the whole sector and owning one slice of it with the volume turned up.
Vanguard's VHT holds a broad healthcare portfolio, charges less in fees and pays a higher yield. State Street's XPH concentrates on pharmaceuticals, has delivered stronger recent gains, and has been the more volatile of the two. That trade-off — cost and breadth against momentum and swing — is the entire decision, and Thursday's tape showed it in miniature.
What the Sept. 10 close says about the two funds
VHT last traded at 311.27, down 0.65% on the day from a prior close of 313.30, with a session range of 311.05 to 313.91. XPH last traded at 68.01, down 1.89% from a prior close of 69.32, moving between 67.91 and 69.06.
That is a gap of roughly 1.24 percentage points between the two on a single down day — a useful, if small, demonstration of the volatility difference the comparison rests on. Measured as a share of the previous close, VHT's intraday range spanned about 0.91% of its value; XPH's spanned about 1.66%, nearly twice as wide. One day proves nothing on its own, but it is consistent with the profile: the narrower, pharma-only book moves more.
The backdrop was broadly negative. The S&P 500, via SPY, closed at $757.83, down 0.60%. The Nasdaq 100 tracker QQQ closed at $708.69, down 1.06%, and the Dow tracker DIA at $520.75, down 0.63%. Against that, VHT was roughly in line with the broad market while XPH lagged it by about 1.29 percentage points — the higher-beta fund doing what higher-beta funds do when the market leans lower.
Fees and yield: the part that compounds quietly
The fee and income advantages sit with Vanguard. VHT charges less and yields more, according to the comparison published by Motley Fool. Neither of those differences will show up in a week or a quarter. Both show up over a decade.
The mechanism is unglamorous. An expense ratio is deducted from fund assets continuously, so it reduces the return you actually receive regardless of whether the market rises or falls. A higher distribution yield, meanwhile, means a larger share of total return arrives as cash that can be spent or reinvested, which matters disproportionately for investors drawing income and for anyone whose reinvestment is automatic.
The structural reason for the yield gap is worth understanding rather than memorizing. A broad healthcare fund owns not just drugmakers but the rest of the sector's machinery: insurers, distributors, device makers, hospital and services companies, plus early-stage biotech. Several of those groups are mature, cash-generative and pay dividends. A pharmaceuticals-focused fund narrows the universe and, depending on how it is constructed, can tilt toward smaller and mid-size drug companies that pay out less or nothing at all.
Concentration is the source of both the gains and the swings
XPH's stronger recent performance and its wider price swings are the same fact seen from two angles. A concentrated pharmaceutical portfolio is exposed to a specific set of catalysts: late-stage trial readouts, regulatory decisions, patent cliffs, pricing policy and drug-pricing politics. When those break favorably across the group, the fund outruns a diversified sector benchmark. When a major readout fails or Washington turns its attention to pricing, there is nothing in the portfolio to cushion the hit.
XPH's stronger recent performance and its wider price swings are the same fact seen from two angles.
A broad healthcare fund dilutes exactly those outcomes. Managed care, medical devices, life-science tools and healthcare distribution do not respond to the same news as a Phase 3 result. The holder of the diversified fund gives up the upside of a pharma-led run in exchange for not needing to have an opinion about which subsector leads next.
There is also a mechanical point about drawdowns. A fund that falls further needs a larger percentage gain to return to where it started, which is why volatility is a genuine cost rather than just an uncomfortable feeling. Higher-volatility funds can and do produce better long-run results, but they demand that the holder stay invested through the bad stretches — and that is a behavioral requirement, not a financial one.
Which investor each fund actually fits
The honest framing is by mandate, not by scoreboard.
- Core sector exposure. If healthcare is a permanent allocation sized as a percentage of the portfolio — something you buy and rebalance rather than trade — the lower-cost, higher-yielding, broader fund is the default. Cost drag and diversification are precisely the variables that matter over a holding period measured in years.
- A view on drugmakers. If the thesis is specifically about pharmaceuticals — pipeline strength, an approval cycle, a policy outcome — then the concentrated fund expresses that view, and the broad fund waters it down. Just size it as a tactical position rather than a core one.
- Income needs. Retirees and anyone spending distributions should weigh the yield difference more heavily than someone reinvesting in a tax-deferred account.
- Overlap risk. Investors who already hold individual large-cap drugmakers may be doubling their exposure with a pharma fund without realizing it. Check the top holdings before adding.
What to watch next
Three things will determine whether XPH's recent edge persists. First, drug-pricing policy, which hits the concentrated fund hardest and the diversified one only partly. Second, rates: healthcare's more speculative corners, including development-stage biotech, are long-duration assets that reprice when rate expectations shift, and the broad market's Thursday decline came alongside pressure on the most rate-sensitive index, the Nasdaq 100. Third, the pace of large-cap pharma catalysts — approvals, readouts and patent expirations — which drive the pharma sleeve directly.
For most investors the practical answer is not either/or. A broad healthcare position can be the base, with a pharma-focused fund layered on only when there is a specific reason to be overweight drugmakers. What should not happen is buying the more volatile fund because it recently went up more, and then selling it the first time it goes down more. On Sept. 10, it did exactly that.
All prices cited are last traded values as of 20:00 GMT on Sept. 10, 2026, with the market closed.
Key facts
- VHT last close: 311.27, -0.65% (as of 20:00 GMT, Sept. 10, 2026)
- XPH last close: 68.01, -1.89% (as of 20:00 GMT, Sept. 10, 2026)
- Fee and yield edge: VHT charges less and yields more than XPH
- Performance edge: XPH has stronger recent gains, with higher volatility
Frequently asked questions
What is the core difference between VHT and XPH?
VHT is a broad healthcare portfolio spanning drugmakers, insurers, device makers and services companies. XPH is focused on pharmaceuticals only. That single structural difference explains the rest of the comparison: VHT is more diversified and pays a higher yield, while XPH is more concentrated, has delivered stronger recent gains, and has been more volatile.
Which fund is cheaper to own?
Vanguard's VHT charges less in fees than State Street's XPH. An expense ratio is deducted from fund assets continuously, so a lower fee reduces the drag on returns every year you hold the fund, in rising and falling markets alike. Over long holding periods that gap compounds, which is why cost matters most for core, buy-and-hold allocations.
How did the two funds perform on Sept. 10, 2026?
VHT closed at 311.27, down 0.65% from a prior close of 313.30, trading between 311.05 and 313.91. XPH closed at 68.01, down 1.89% from 69.32, with a range of 67.91 to 69.06. Broad benchmarks also fell: SPY closed at $757.83, down 0.60%, and QQQ at $708.69, down 1.06%.
Why does XPH yield less than VHT?
A pharmaceuticals-only portfolio excludes several income-generating parts of the healthcare sector, such as insurers, distributors and mature device makers, and depending on construction may tilt toward smaller drug companies that pay little or no dividend. A broader healthcare fund captures more of the sector's dividend-paying, cash-generative businesses, lifting its distribution yield.
Does higher volatility mean XPH is a worse investment?
Not necessarily. Volatility is a measure of how widely prices swing, not a verdict on returns — XPH has delivered stronger recent gains despite it. But larger drawdowns require larger percentage recoveries and demand that holders stay invested through bad stretches. Volatility is best treated as a position-sizing question rather than a disqualifier.
Can an investor reasonably own both funds?
Yes. A common approach is to use the broad healthcare fund as the core allocation and add a pharmaceuticals-focused fund only when there is a specific reason to be overweight drugmakers. The main caution is overlap: investors already holding large-cap pharmaceutical stocks directly may be doubling exposure without intending to, so check top holdings first.
Sources
Photo: Zalasem1 · BY 4.0 — source
